Good
Mostly Aligned
Patient Risk:
Low
Summary
Most mechanism, lipid-lowering indication, and drug-interaction timing statements align with the provided label sections. Several claims are unsupported or not represented in the provided excerpts (e.g., diarrhea indication, multiple specific adverse effects, availability/supply, and class comparisons to colesevelam).
Category Scores
Accurate Statements
Colestipol binds bile acids in the intestines so they can be removed from the body.
CLINICAL PHARMACOLOGY: binds bile acids in the intestine forming a complex that is excreted in the feces.
Clinicians use colestipol primarily to help lower cholesterol levels (particularly LDL).
INDICATIONS AND USAGE: adjunctive therapy to diet to reduce elevated serum total and LDL-C in primary hypercholesterolemia.
Because bile-acid sequestrants bind bile acids, they can interfere with absorption of certain medications in some patients.
DRUG INTERACTIONS: may delay or reduce the absorption of concomitant oral medication; interval should be as long as possible.
Because bile-acid sequestrants bind bile acids, they can interfere with absorption of fat-soluble vitamins in some patients.
PRECAUTIONS: may reduce absorption of folic acid and fat soluble vitamins such as A, D, and K.
Colestipol can reduce absorption of other medications by binding them in the gut.
DRUG INTERACTIONS: in vitro binding to a number of drugs; COLESTID Tablets may delay or reduce absorption of concomitant oral medication.
Colestipol doses should be separated from other oral drugs by several hours to avoid drug interactions.
DRUG INTERACTIONS and DOSAGE AND ADMINISTRATION: take other drugs at least one hour before or four hours after COLESTID Tablets; interval should be as long as possible.
Unsupported Statements
Colestipol can be used for certain bile-acid–related diarrhea conditions, depending on the patient and prescribing decision.
No label excerpt provided for bile-acid–related diarrhea indications.
Common side effects of bile-acid sequestrants include constipation, bloating, gas, nausea, and stomach discomfort.
Provided label excerpts include constipation-related precautions, but do not list bloating, gas, nausea, or stomach discomfort as 'common side effects.'
Colestipol is widely available as a medication product.
No label excerpt provided addressing availability.
Colestipol availability may depend on formulation (for example, tablet vs. granules) and local pharmacy supply.
No label excerpt provided addressing availability by formulation or pharmacy supply.
Contradictions
Low
AI Statement
Colestipol is in the same drug class as other bile-acid sequestrants such as cholestyramine and colesevelam.
Label Reference
Only cholestyramine is explicitly referenced in the provided label excerpts; colesevelam is not confirmed.
Low
AI Statement
Colestipol is a bile-acid sequestrant medication.
Label Reference
Provided excerpts support bile-acid binding/excretion mechanism but the exact phrase 'bile-acid sequestrant' is not explicitly confirmed in the provided sections.
Important Omissions
No adverse reaction listing beyond constipation/worsening constipation; monitoring and management details for constipation/fecal impaction were not captured in the AI claims.
Importance:
Moderate
No mention that colestipol has no clinically significant effect on serum triglycerides overall, but may raise triglycerides in some patients.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims largely describe mechanism, lipid indication, and drug interaction timing consistent with the provided label excerpts. Unsupported statements relate to non-labeled diarrhea use, multiple specific adverse effects not verified, and availability details, which are less directly safety-critical relative to the label.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Some claims are not supported by the provided label excerpts (notably bile-acid–related diarrhea use, several specific 'common side effects,' and availability assertions). Also, class comparison to colesevelam is not confirmed, and the exact 'bile-acid sequestrant' wording is not explicitly present in the provided sections.
Suggested Improvement
Restrict claims to mechanisms and indications explicitly supported by the provided label excerpts; remove or qualify unsupported diarrhea and adverse-effect specifics; limit drug-class comparisons to agents explicitly referenced (e.g., cholestyramine) in the provided label text.